Sight Sciences, Inc.
3000 Sand Hill Road
Building 3, Suite 105
Menlo Park
California
94025
United States
Tel: 415-889-0550
Website: http://www.sightsciences.com/
Email: info@sightsciences.com
About Sight Sciences, Inc.
Sight Sciences, Inc. is a privately held ophthalmic medical device company whose mission is to revolutionize how we think about and treat the leading causes of eye disease. Founded in 2006, headquartered in Menlo Park, CA, and supported by leading medical technology and private equity investors, Sight Sciences is developing a range of highly innovative products that share a universal value proposition:• Meeting a Massive Unmet Clinical Need in Ophthalmology
• Addressing the Underlying Physiology of Disease
• Delivering Unparalleled Product Usability
• Offering a High Socioeconomic Impact
• Creating a Paradigm Shift in Treatment from Pharmaceuticals to Devices
YEAR FOUNDED:
2010
LEADERSHIP:
Founder and CEO: Paul Badawi
Founder and CTO: David Badawi
CMO: Robert Stamper
PRODUCTS:
VISCO360
TRAB360
115 articles about Sight Sciences, Inc.
-
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients
11/3/2022
Sight Sciences, Inc. today announced International Ophthalmology has published clinical data demonstrating the safety and effectiveness of the OMNI Surgical System.
-
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
10/20/2022
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2022, after the market close on Thursday, November 10, 2022.
-
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
9/29/2022
Sight Sciences, Inc. today announced Clinical Ophthalmology has published data from a subgroup analysis of the OLYMPIA trial.
-
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting
9/28/2022
Sight Sciences, Inc., announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery during this year’s annual AAO convention at McCormick Place in Chicago, IL.
-
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
9/16/2022
Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Milan, Italy on Friday, September 16 through Tuesday, September 20.
-
Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®
9/13/2022
Sight Sciences, Inc. announced the completion of enrollment in the SAHARA Trial, a first of its kind outcomes study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis® dry eye eyedrops.
-
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
9/2/2022
Sight Sciences, Inc. (Nasdaq: SGHT) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
-
Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
8/25/2022
Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
-
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
8/23/2022
Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, announced the launch of SION, a surgical instrument representing a new chapter in goniotomy innovation and practice.
-
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
8/16/2022
Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, announced 36-month post-surgery follow-up results of the OMNI® Surgical System.
-
Sight Sciences Reports Second Quarter 2022 Financial Results
8/11/2022
Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, reported financial results for the second quarter ended June 30, 2022.
-
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
7/28/2022
Sight Sciences, Inc today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022.
-
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors
7/19/2022
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022.
-
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
5/31/2022
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patient care.
-
Sight Sciences Reports First Quarter 2022 Financial Results
5/10/2022
Sight Sciences, Inc. reported financial results for the quarter ended March 31, 2022.
-
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
4/29/2022
Sight Sciences, Inc. an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced plans to participate in the upcoming Bank of America Healthcare Conference.
-
Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
4/20/2022
Sight Sciences, Inc. announced that data from clinical studies of the OMNI® Surgical System will be presented at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting.
-
Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022
4/14/2022
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022.
-
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results
3/24/2022
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021.
-
Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
3/24/2022
Sight Sciences, Inc. (Nasdaq: SGHT), today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI® Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject®, in lowering IOP in adult patients with open-angle glaucoma.